Maa: Norja
Kieli: norja
Lähde: Statens legemiddelverk
Kobolt(II)kloridheksahydrat / Eksametazim
GE HEALTHCARE AS
V09AA01
Kobolt(II)kloridheksahydrat / Eksametazim
Preparasjonssett til radioaktive legemidler
5 sett
C
Markedsført
2001-06-01
_ _ _ _ _ _ _Page 1 of 11 _ SUMMARY OF PRODUCT CHARACTERISTICS FOR STABILISED CERETEC, KIT FOR RADIOPHARMACEUTICAL PREPARATION 1. NAME OF THE MEDICINAL PRODUCT Stabilised Ceretec 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains exametazime 500 micrograms. Stabilised Ceretec is reconstituted with Sodium Pertechnetate ( 99m Tc) Injection Ph.Eur. (not included in this kit) to prepare stabilised Technetium ( 99m Tc) Exametazime Injection. Excipients: The product before reconstitution contains sodium: 1.77 mg/vial. This needs to be taken into consideration for patients on a controlled sodium diet. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Kit for radiopharmaceutical preparation White powder 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This medicinal product is for diagnostic use only. After radiolabeling with Sodium Pertechnetate ( 99m Tc) Injection, the solution of technetium ( 99m Tc) exametazime is indicated in adults for: Neurology Technetium ( 99m Tc) Exametazime Injection is indicated for use with single photon emission tomography (SPECT). In brain perfusion SPECT, the diagnostic target is detection of abnormalities of regional cerebral blood flow, including: - Evaluation of patients with cerebrovascular disease (specifically acute stroke, chronic ischaemia and transient ischaemic attack); - Presurgical lateralisation and localisation of epileptogenic foci; - Evaluation of patients with suspected dementia (specifically Alzheimer’s disease and frontotemporal dementia); - Adjuvant technique in the diagnosis of brain death _ _ _ _ _Page 2 of 11 _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _ _ _Adults_555-1110 MBq by direct intravenous injection Normally a once-only diagnostic procedure _ Paediatric population _ Technetium-99m exametazime with the cobalt chloride solution is not recommended for administration to children. Safety and effectiveness of the cobalt solution has not been established in the paediatric population. Method of administration This me Lue koko asiakirja